Literature DB >> 19394839

Development of a new multi-modal Monte-Carlo radiotherapy planning system.

H Kumada1, T Nakamura, M Komeda, A Matsumura.   

Abstract

A new multi-modal Monte-Carlo radiotherapy planning system (developing code: JCDS-FX) is under development at Japan Atomic Energy Agency. This system builds on fundamental technologies of JCDS applied to actual boron neutron capture therapy (BNCT) trials in JRR-4. One of features of the JCDS-FX is that PHITS has been applied to particle transport calculation. PHITS is a multi-purpose particle Monte-Carlo transport code. Hence application of PHITS enables to evaluate total doses given to a patient by a combined modality therapy. Moreover, JCDS-FX with PHITS can be used for the study of accelerator based BNCT. To verify calculation accuracy of the JCDS-FX, dose evaluations for neutron irradiation of a cylindrical water phantom and for an actual clinical trial were performed, then the results were compared with calculations by JCDS with MCNP. The verification results demonstrated that JCDS-FX is applicable to BNCT treatment planning in practical use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394839     DOI: 10.1016/j.apradiso.2009.03.028

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  2 in total

1.  Calculating and estimating second cancer risk from breast radiotherapy using Monte Carlo code with internal body scatter for each out-of-field organ.

Authors:  Takeshi Takata; Kenshiro Shiraishi; Shinobu Kumagai; Norikazu Arai; Takenori Kobayashi; Hiroshi Oba; Takahide Okamoto; Jun'ichi Kotoku
Journal:  J Appl Clin Med Phys       Date:  2020-10-30       Impact factor: 2.102

2.  Simulation study on radiation exposure of emergency medical responders from radioactively contaminated patients.

Authors:  Takakiyo Tsujiguchi; Yoko Suzuki; Mizuki Sakamoto; Kazuki Narumi; Katsuhiro Ito; Hiroshi Yasuda; Shinji Tokonami; Ikuo Kashiwakura
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.